Physical Therapists in Hillsboro, TX Accepting Medicare
6 Physical Therapists found. Showing 1 - 6
 Dr. Matthew Douglas Peacock, PT, DPT Physical Therapist - Cardiopulmonary Medicare: Accepting Medicare Assignments Practice Location: 1305 E Elm St, Hillsboro, TX 76645 Phone: 254-582-2713 Fax: 254-582-2717 |
 Dr. Amanda Basse, PT, DPT Physical Therapist Medicare: Not Enrolled in Medicare Practice Location: 1305 E Elm St, Hillsboro, TX 76645 Phone: 254-582-2713 |
Tiffany Polston, PT Physical Therapist Medicare: Not Enrolled in Medicare Practice Location: 101 Circle Dr, Hillsboro, TX 76645 Phone: 254-580-8840 |
Dr. Garrett Lee Forero Morales, DPT Physical Therapist Medicare: Not Enrolled in Medicare Practice Location: 1305 E Elm St, Hillsboro, TX 76645 Phone: 254-582-2713 |
Shane Patrick Dugan, PT, DPT Physical Therapist Medicare: Medicare Enrolled Practice Location: 101 Circle Dr, Hillsboro, TX 76645 Phone: 254-580-8840 |
Jeffrey Tabor Physical Therapist Medicare: Not Enrolled in Medicare Practice Location: 101 Circle Dr, Hillsboro, TX 76645 Phone: 254-733-5910 |
News Archive
During a pandemic, states' patchwork of crisis plans could mean uneven care
A possible coronavirus pandemic could overwhelm the nation's hospitals and force doctors into difficult decisions about how to allocate limited resources. Yet, experts say, only a handful of states have done the work necessary to prepare for such worst-case scenarios.
British doctors say cut the time limit for abortions
At present the current limit for abortions is 24 weeks, but a survey of 1,000 GPs by Marie Stopes International, found 65 per cent thought the current 24-week abortion limit should be cut; of these, 62 per cent said the upper limit should remain within 20 to 23 weeks.
Sequenom CMM completes build-out, validation of additional lab facility in Raleigh-Durham, NC
Sequenom, Inc., a life sciences company providing innovative genetic analysis solutions, today announced that its wholly owned subsidiary, the Sequenom Center for Molecular Medicine, has completed the build-out and validation of an additional laboratory location in Raleigh-Durham, NC, and is now processing patient samples commercially.
Sequential treatment with Entecavir and Lamivudine results in rebound of hepatitis B virus
A two-year trial of entecavir followed by lamivudine (LAM) in patients with chronic hepatitis B virus (HBV) infection resulted in a virologic rebound rate of 24% and 12% drug-resistance rate. Patients who continued on entecavir therapy throughout the study period had undetectable HBV DNA at the two-year endpoint. Details of this trial are published in the April issue of Hepatology, a journal published by Wiley-Blackwell on behalf of the American Association for the Study of Liver Diseases..
› Verified 4 days ago
Physical Therapists
Speech-Language Pathologists
Podiatrists
Chiropractors
Optometrists
Occupational Therapists